Dubai, United Arab Emirates, 15 November 2012 -During the 3rd Annual Emirates Cardiac Society Congress that was recently held in Dubai, Bayer Healthcare announced the registration and availability in the UAE of Rivaroxaban, a new oral anticoagulant that potentially prevents strokes and overcomes the limitations of current treatments that have been prescribed since the 1950s.
The new anticoagulant, which is now available in 110 countries, has been developed to prevent and treat dangerous blood clots, and holds promise for millions of patients around the world with, or at threat from venous or arterial blood clots. It is also approved by leading international medical agencies such as the Food and Drug Association in the US(FDA) and European Medicines Agency (EMA).
In his keynote in the congress, Dr. Wael AbdulrahmanAlmahmeed, Consultant Cardiologist, Sheikh Khalifa Medical City, Abu Dhabi, explained: "Since the 1950s, the standard of care for stroke prevention in Atrial Fibrillation (AF) and venous thromboembolism, which encompasses DVT, has involved VKAs including warfarin. Though effective, warfarin can lead to unpredictable levels of anticoagulation and requires the need for frequent blood monitoring and dose adjustments, not to mention drug interactions and dietary restrictions."
Dr.Frank SonntagConsultant Cardiology and Member of the Scientific Advisory Board of the German Heart Foundation Dr. Sonntag said: "The new drug - Rivaroxaban - simplifies protection with a simple fixed once daily dosing, rapid onset of action without the need for routine coagulation monitoring or frequent dose adjustment, low risk of drug-drug interactions and limited potential of dietary restrictions."
Clots are a devastating threat that affects millions globally and protection against dangerous clots is important both for stroke prevention and treatment. Reports indicate that in every 13 seconds someone has an AF related stroke in the world and venous thromboembolism is the immediate cause of death of 10% of patients who die in hospital."
The3rd Annual Emirates Cardiac Society Congress in Dubai was attended by leading medical experts in the field of cardiology and stroke prevention in atrial fibrillation. The Congress had key topics addressed by international and regional speakers. It included plenary sessions on Cardiac Arrhythmia, Coronary Artery Disease, Valvular Heart Disease, Heart Failure and Prevention of Cardiovascular Disease Sessions. For the third consecutive year the Congress is hosted by the Emirates Cardiac Society.
The Emirates Cardiac Society is a network of cardiologists in the UAE that work under the umbrella of the Emirates Medical Association. The society's mission is to educate the public and health care professionals in reducing the burden of cardiovascular disease in the UAE.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
For more details Contact:
Nadine Fanous, Tel. +20 10 1944-3104
E-Mail: nadine.fanous@bayer.com
Find more information at www.bayerpharma.com
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.
© Press Release 2012
